NR3C2 and type 2 diabetes mellitus: Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) selective for the MR.1 In three large outcome trials, finerenone improved cardiovascular (CV) and kidney outcomes in patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), and reduced the risk for the composite endpoint of total heart failure events and CV death in heart failure patients with ejection fraction ≥40.2–4 In animal models of cardiorenal disease, finerenone treatment ameliorated cardiac and renal hypertrophy, reduced sodium retention and proteinuria.